Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis
|
By LabMedica International staff writers Posted on 04 Mar 2021 |

Illustration
Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell analysis and further explore AI technology in vitro diagnostics.
Through this cooperation, the two parties will further develop blood cell morphology testing equipment and system applications with world-class imaging quality and cell recognition capabilities. Large-scale production in the future is expected to relieve the work pressure faced by primary endoscopy physicians, and improve the diagnosis and diagnosis of blood diseases.
Tencent AI Lab will use machine learning, computer vision and other cutting-edge algorithms and the experience of its research scientists, Tencent Cloud’s comprehensive solutions, combined with Mindray Medical’s expertise in slide processing, imaging systems, integrated design, and clinical experts, massive data and other aspects, to jointly develop an automated blood cell analyzer in order to further improve accuracy in results. The automated blood cell analyzer will detect cell quality changes and have high levels of cell identification capability. At the same time, it will provide a cost advantage as compared to rival products with higher prices.
In addition to morphological testing, Tencent AI Lab will also work with Mindray Medical to explore the integration and application of AI technology in other areas of in vitro diagnostics, such as urine analysis, smart laboratory, and in vitro diagnostic big data, in order to provide better quality medical equipment and services.
“AI+Medical/Pharmaceutical" is one of Tencent's AI Lab's long-term core research directions. We are very happy to cooperate with industry top partners like Mindray to enable technology to help medical care, assist doctors, and serve patients,” said Yang Wei, General Manager of Tencent AI Lab.
“With Mindray’s deep understanding of clinical needs and accumulation of detection technology over the years, and Tencent’s leading exploration in artificial intelligence technology, The results of the cooperation between the two parties will greatly improve the ability of clinical intelligent detection,” said Yan Huawen, General Manager of Mindray’s IVD Division.
Related Links:
Mindray
Tencent AI Lab
Through this cooperation, the two parties will further develop blood cell morphology testing equipment and system applications with world-class imaging quality and cell recognition capabilities. Large-scale production in the future is expected to relieve the work pressure faced by primary endoscopy physicians, and improve the diagnosis and diagnosis of blood diseases.
Tencent AI Lab will use machine learning, computer vision and other cutting-edge algorithms and the experience of its research scientists, Tencent Cloud’s comprehensive solutions, combined with Mindray Medical’s expertise in slide processing, imaging systems, integrated design, and clinical experts, massive data and other aspects, to jointly develop an automated blood cell analyzer in order to further improve accuracy in results. The automated blood cell analyzer will detect cell quality changes and have high levels of cell identification capability. At the same time, it will provide a cost advantage as compared to rival products with higher prices.
In addition to morphological testing, Tencent AI Lab will also work with Mindray Medical to explore the integration and application of AI technology in other areas of in vitro diagnostics, such as urine analysis, smart laboratory, and in vitro diagnostic big data, in order to provide better quality medical equipment and services.
“AI+Medical/Pharmaceutical" is one of Tencent's AI Lab's long-term core research directions. We are very happy to cooperate with industry top partners like Mindray to enable technology to help medical care, assist doctors, and serve patients,” said Yang Wei, General Manager of Tencent AI Lab.
“With Mindray’s deep understanding of clinical needs and accumulation of detection technology over the years, and Tencent’s leading exploration in artificial intelligence technology, The results of the cooperation between the two parties will greatly improve the ability of clinical intelligent detection,” said Yan Huawen, General Manager of Mindray’s IVD Division.
Related Links:
Mindray
Tencent AI Lab
Latest Industry News
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
Channels
Clinical Chemistry
view channel
Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Counterfeit and substandard medicines remain a serious global health threat, with World Health Organization estimates suggesting that 10.5% of medicines in low- and middle-income countries are either fake... Read more
Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
Acute recreational drug toxicity is a frequent reason for emergency department visits, yet clinicians rarely have access to confirmatory toxicology results in real time. Instead, treatment decisions are... Read moreMolecular Diagnostics
view channel
New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids
Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more
AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy
Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Rapid Test Promises Faster Answers for Drug-Resistant Infections
Drug-resistant pathogens continue to pose a growing threat in healthcare facilities, where delayed detection can impede outbreak control and increase mortality. Candida auris is notoriously difficult to... Read more
CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
Antibiotic resistance has accelerated into a global health crisis, with projections estimating more than 10 million deaths per year by 2050 as drug-resistant “superbugs” continue to spread.... Read more
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read morePathology
view channel
Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more







